Loading stock data…
$5.85-0.01 (-0.17%)
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
Gyre Therapeutics, Inc. in the Healthcare sector is trading at $5.85 with a market capitalization of $713M. Wall Street consensus targets $18.67 (3 analysts), implying a +219.1% move over the next 12 months. The stock is currently near its 52-week low of $5.44, remaining 16.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $29.11M↑ | $22.52M↓ | $37.20M↑ | $30.56M↑ | $29.73M |
| Gross Profit | $26.90M↑ | $21.29M↓ | $35.45M↑ | $28.94M↑ | $28.58M |
| Operating Income | -$13.86M↓ | -$6.80M↓ | $120,000↓ | $6.93M↑ | -$2.24M |
| Net Income | -$10.61M↓ | -$8.69M↓ | -$1.72M↓ | $3.61M↑ | $598,000 |
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug...